Search Result

Results for "

diabetic model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Kinase (1) Adrenergic Receptor (1) Akt (2) Aldehyde Dehydrogenase (ALDH) (1) Angiotensin-converting Enzyme (ACE) (2) Apoptosis (2) Biochemical Assay Reagents (1) Cholinesterase (ChE) (2) Deubiquitinase (1) Endogenous Metabolite (4) Fluorescent Dye (1) Free Fatty Acid Receptor (1) Glucokinase (2) GLUT (1) Glutaminase (1) Glycosidase (1) GPR84 (1) HSP (1) Insulin Receptor (1) Lipoxygenase (1) LXR (1) MDM-2/p53 (1) Potassium Channel (2) PPAR (5) Reactive Oxygen Species (1) ROR (1) Sodium Channel (1) TGF-β Receptor (1) Tie (2) Trk Receptor (1) VEGFR (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (8) Metabolic Disease (32) Neurological Disease (8)

By Targets:

Adenosine Kinase (1)

Adrenergic Receptor (1)

Akt (2)

Aldehyde Dehydrogenase (ALDH) (1)

Angiotensin-converting Enzyme (ACE) (2)

Apoptosis (2)

Biochemical Assay Reagents (1)

Cholinesterase (ChE) (2)

Deubiquitinase (1)

Endogenous Metabolite (4)

Fluorescent Dye (1)

Free Fatty Acid Receptor (1)

Glucokinase (2)

GLUT (1)

Glutaminase (1)

Glycosidase (1)

GPR84 (1)

HSP (1)

Insulin Receptor (1)

Lipoxygenase (1)

LXR (1)

MDM-2/p53 (1)

Potassium Channel (2)

PPAR (5)

Reactive Oxygen Species (1)

ROR (1)

Sodium Channel (1)

TGF-β Receptor (1)

Tie (2)

Trk Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (8)

Metabolic Disease (32)

Neurological Disease (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164781

KOTX1	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .

HY-107863

Fructooligosaccharides Oligolevulose	Biochemical Assay Reagents	Metabolic Disease
Fructooligosaccharides (Oligolevulose) is a beneficial sugar which can be produced by the microbial flora. Fructooligosaccharides had no significant effect on blood glucose, blood lipid and serum acetate in diabetic model .

HY-101666

HBX 41108 2 Publications Verification	Deubiquitinase Apoptosis MDM-2/p53	Metabolic Disease Cancer
HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC₅₀ of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research .

HY-76383

LR-90	Others	Metabolic Disease Inflammation/Immunology
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .

HY-160186

20-SOLA	Others	Cardiovascular Disease
20-SOLA is the first water soluble and orally active 20-HETE antagonist. 20-SOLA greatly ameliorates changes in blood pressure and renal injury associated with a streptozotocin (STZ (HY-13753))-diabetic mouse model. 20-SOLA also is a GPR75 receptor blocker. 20-SOLA can be used for the research of cardiovascular pathologies .

HY-122120

Rafabegron AJ‐9677	Adrenergic Receptor	Metabolic Disease
Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .

HY-14923

Ilepatril AVE 7688	Angiotensin-converting Enzyme (ACE)	Metabolic Disease
Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .

HY-123409

Nicousamide	TGF-β Receptor	Metabolic Disease
Nicousamide is a potent inhibitor of TGF-β RII phosphorylation. Nicousamide can be used to study renal fibrosis in animal models of diabetic nephropathy .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-125327

YM-543	Others	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-128442

Phenyl sulfate Phenyl hydrogen sulfate	Endogenous Metabolite	Metabolic Disease
Phenyl sulfate is an orally active gut microbiota-derived metabolite. Phenyl sulfate induces albuminuria and podocyte damage in experimental models of diabetes. Phenyl sulfate can be used as a disease marker and future therapeutic target in diabetic kidney disease .

HY-B0093A

Benazepril hydrochloride 1 Publications Verification CGS14824A	Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species Akt	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Benazepril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .

HY-13999A1

NSI-189 phosphate	Trk Receptor Akt	Neurological Disease
NSI-189 phosphate is the phosphate salt form of NSI-189 (HY-13999). NSI-189 phosphate stimulates the neurogenesis of neural stem cells. NSI-189 phosphate exhibits neuroprotective effect in Streptozotocin (HY-13753)-induced diabetic mouse model, improves neurological function and cognitive ability after stroke in rat middle cerebral artery occlusion (MCAo) model, and exhibits antidepressant efficacy .

HY-138007

SR-1903	ROR PPAR LXR	Metabolic Disease Inflammation/Immunology
SR-1903 is an inverse agonist of RORγ and PPARγ (IC₅₀ of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .

HY-145559

Cemdomespib KU-596	HSP	Metabolic Disease
Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response .

HY-P10580

Vasculotide	Tie	Infection Metabolic Disease Inflammation/Immunology Cancer
Vasculotide, an angiopoietin-1 mimetic, is a Tie-2 activator and induces Tie-2 phosphorylation. Vasculotide has anti-inflammatiory effect and anti-permeability. Vasculotide ameliorates endotoxin-induced endothelial barrier dysfunction. Vasculotide promotes angiogenesis in a mouse model of diabetic ulcer. Vasculotide protects mice from vascular leakage and reduces mortality in murine abdominal sepsis. Vasculotide decreases microvascular leakage and improves microcirculatory perfusion in a rat model of hemorrhagic shock .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-P10580A

Vasculotide TFA	Tie	Infection Metabolic Disease Inflammation/Immunology Cancer
Vasculotide TFA, an angiopoietin-1 mimetic, is a Tie-2 activator and induces Tie-2 phosphorylation. Vasculotide has anti-inflammatiory effect and anti-permeability. Vasculotide TFA ameliorates endotoxin-induced endothelial barrier dysfunction. Vasculotide TFA promotes angiogenesis in a mouse model of diabetic ulcer. Vasculotide TFA protects mice from vascular leakage and reduces mortality in murine abdominal sepsis. Vasculotide TFA decreases microvascular leakage and improves microcirculatory perfusion in a rat model of hemorrhagic shock .

HY-161682

GPR84 antagonist 9	GPR84	Neurological Disease
GPR84 antagonist 9 (compound 320) is an orally active GPR84 antagonist with the IC₅₀ of 0.012 μM. GPR84 antagonist 9 can be used for study of inflammatory-driven pain diseases .

HY-168214

Kv7.2/Kv7.3 agonist 1	Potassium Channel	Neurological Disease
Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC₅₀ of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED₅₀ of 12.02 and 9.63 mg/kg .

HY-106181A

Rivoglitazone hydrochloride R-106056 hydrochloride	PPAR	Metabolic Disease
Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .

HY-160602

CPL207280	Free Fatty Acid Receptor	Metabolic Disease
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .

HY-126969

C333H	PPAR	Metabolic Disease
C333H is a selective PPARγ modulator with insulin-sensitizing and hypoglycemic activities. C333H exhibits similar insulin-sensitizing effects to thiazolidinediones (TZDs) in diabetic mouse models without significantly increasing body weight or adipose tissue weight. C333H increases circulating high molecular weight adiponectin isoform levels in diabetic db/db mice, reduces serine phosphorylation of PPARγ 273 in brown adipose tissue, and selectively modulates the expression of specific PPARγ target genes in adipose tissue. Express. C333H exhibits weak recruitment of co-activators and weak dissociation of co-repressors in vitro. These properties suggest that C333H may be a potential inhibitor of type 2 diabetes .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-162639

α-Glucosidase-IN-68	Glycosidase Cholinesterase (ChE)	Neurological Disease Metabolic Disease
α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC₅₀ of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC₅₀ of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models .

HY-149837

PRO-F	Fluorescent Dye	Inflammation/Immunology
PRO-F is a photoactivable H₂S donor with ROS scavenging ability. PRO-F can be activated by light to produce fluorescent signal, for real-time tracking of released H₂S. PRO-F activation doesn’t consume endogenous substances. deliver H₂S in an intracellular environment to protect cells from excessive reactive oxygen species (ROS) induced damage. PRO-F shows enhancement on chronic wound healing, researched in diabetic models as well .

HY-159962

TGase2-IN-1	Glutaminase	Metabolic Disease
TGase2-IN-1 (Compound 22) is an orally active inhibitor for TGase2 with an IC₅₀ of 1.12 μM. TGase2-IN-1 inhibits TGase2 in human retinal microvascular endothelial cells with an IC₅₀ of 0.07 μM. TGase2-IN-1 exhibits 74.6% oral bioavailability. TGase2-IN-1 inhibits retinal vascular leakage in mouse Streptozotocin (HY-13753)-induced diabetic model .

HY-111310

ML351 1 Publications Verification	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

HY-139792

Besigliptin tosylate SHR117887	Others	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-113089

Epsilon-(gamma-glutamyl)-lysine H-Glu(H-Lys-OH)-OH; γ-Glu-ε-Lys	Endogenous Metabolite	Metabolic Disease
Epsilon-(gamma-glutamyl)-lysine is an N(6)-acyl-L-lysine derivative. The enzyme tissue transglutaminase (tTg) helps the formation of epsilon-(gamma-glutamyl)lysine bonds between ECM components in some disease, such as non-diabetic kidney, glaucoma filtration .

HY-113089A

Epsilon-(gamma-glutamyl)-lysine TFA H-Glu(H-Lys-OH)-OH TFA; γ-Glu-ε-Lys TFA	Endogenous Metabolite	Metabolic Disease
Epsilon-(gamma-glutamyl)-lysine (H-Glu(H-Lys-OH)-OH) TFA is an N(6)-acyl-L-lysine derivative. The enzyme tissue transglutaminase (tTg) helps the formation of epsilon-(gamma-glutamyl)lysine bonds between ECM components in some disease, such as non-diabetic kidney, glaucoma filtration .

HY-116005

A-286501	Adenosine Kinase	Neurological Disease Inflammation/Immunology
A-286501 is an orally active and potent carbocyclic nucleoside adenosine kinase inhibitor with an IC₅₀ value of 0.47 nM, which shows analgesic and anti-inflammatory effects. A-286501 reduces nociception in animal models of acute (thermal), inflammatory (formalin and carrageenan) and neuropathic (L5/L6 nerve ligation and streptozotocin-induced diabetic) pain. A-286501 also reduces Carrageenan (HY-125474)-induced paw edema and myeloperoxidase activity in the injured paw. A-286501 is promising for research of analgesic and anti-inflammatory agents .

HY-P99116

Faricimab RG7716	VEGFR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .

HY-145549

C20 Sphingomyelin (d18:1/20:0) N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)	Endogenous Metabolite	Endocrinology
C20 Sphingomyelin (d18:1/20:0) (N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)) is a naturally occurring sphingolipid. C20 Sphingomyelin (d18:1/20:0) levels are upregulated in the hippocampus of streptozotocin (HY-13753)-induced diabetic rats and in human plasma, positively correlating with insulin resistance in obese humans. C20 Sphingomyelin (d18:1/20:0) is also upregulated in the liver of a mouse model of Niemann-Pick C1 disease, a neurodegenerative cholesterol sphingolipid lysosomal storage disorder.

HY-162578

PPARα/γ agonist 4	PPAR	Metabolic Disease
PPARα/γ agonist 4 (Compound (S)-7) is an orally active dual potent agonist of PPARα and PPARγ, with EC₅₀ values of 0.061 μM and 1.42 μM respectively. PPARα/γ agonist 4 acts through an insulin-independent mechanism and exhibits mitochondrial pyruvate carrier inhibition and anti-diabetic properties. PPARα/γ agonist 4 is expected to be used in research for dyslipidemic type 2 diabetes .

HY-W027553

Ipidacrine NIK-247 free base	Cholinesterase (ChE) Potassium Channel Sodium Channel	Neurological Disease Metabolic Disease
Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC₅₀ values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K ⁺ and Na ⁺-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .

HY-120974

α-lipoic acid derivative 1	GLUT	Metabolic Disease
α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes .

Cat. No.	Product Name	Type